Clinical Trials
13 trialsNCT04878094 2026-05-20
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT06732388 2026-05-13
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT04864067 2026-05-08
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Phase 2 Completed
NCT07445828 2026-04-30
Lynch syndrome
Region Skane
Not yet recruiting
NCT05660421 2026-04-27
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT07206589 2026-04-17
Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial
Mayo Clinic
Phase NA Not yet recruiting
NCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT03641313 2026-04-13
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06637462 2026-03-18
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT07472868 2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3 Not yet recruiting
NCT07462247 2026-03-12
Establishment of Image Database for Early Upper Gastrointestinal Cancer, Precancerous Lesions, and Precancerous Conditions
Changhai Hospital
Recruiting
NCT03819296 2026-03-11
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05078866 2026-03-03
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting